Pasithea Therapeutics Corp KTTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.45
- Day Range
- $0.47–0.52
- 52-Week Range
- $0.28–2.06
- Bid/Ask
- $0.45 / $0.51
- Shares Outstanding
- 33.41M
- Market Cap
- $15.81M
- Volume/Avg
- 6,008 / 823,545
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.pasithea.com
Valuation
|
Metric
|
KTTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KTTA
|
|---|---|
Quick Ratio | 33.84 |
Current Ratio | 35.40 |
Interest Coverage | — |
Quick Ratio
KTTA
Profitability
|
Metric
|
KTTA
|
|---|---|
Return on Assets (Normalized) | −53.97% |
Return on Equity (Normalized) | −58.10% |
Return on Invested Capital (Normalized) | −60.53% |
Return on Assets
KTTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xRq&V< | LOCK|!Jl^G | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|r?W@>F | LOCK|%wXp | $71B | |||
| argenx SE ADR
ARGX
| LOCK|KBSHZ# | LOCK|c$^ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|YRc%WK | LOCK|Hq | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?K!t#nC | LOCK|&>!b# | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|w#K^zp! | LOCK|gGb&t | $26B | |||
| Moderna Inc
MRNA
| LOCK|??S>#G | LOCK|T&# | $25B | |||
| Incyte Corp
INCY
| LOCK|MG>X@? | LOCK|^XZ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@Mgx%Q | LOCK|$^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%lv&?Z | LOCK|<D | $16B |
United States